PIK3CA and Ewing sarcoma: In this study, we evaluated the in vitro activity of the pan-class I PI3K inhibitor buparlisib alone and in combination with other targeted agents in three common pediatric sarcomas: Ewing sarcoma (ES), osteosarcoma (OS), and rhabdomyosarcoma (RMS).